secwatch.observer — SEC 8-K summary
======================================

Issuer:     Profusa, Inc. (PFSA)
CIK:        0001859807
Form:       8-K
Filed at:   2025-07-18T23:59:59+00:00
Accession:  0001213900-25-065686
Event type: m_and_a
Sentiment:  neutral
Materiality: 0.90
Item codes: 1.01, 2.01, 2.03, 3.02, 9.01, 3.03, 5.01, 5.02, 5.06, 8.01
LLM model:  deepseek-v4-flash:cloud@v2

NorthView Acquisition Corp closes merger with Profusa, Inc., becoming Profusa, Inc.
--------------------------------------------------------------------------------

- Profusa valued at $155M; exchange ratio of 0.94 shares of new common stock per Profusa share.
- Issued $10M principal PIPE convertible note to Ascent Partners at 10% OID, 18-month maturity.
- Founder shares locked up for 8 months; other lock-up periods from 6 to 12 months.
- Profusa is a clinical-stage digital health company with CE-marked Lumee Oxygen and Lumee Glucose in trials.
- PIPE Investors subject to lock-up and registration rights; security interest granted on assets.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1859807/000121390025065686/0001213900-25-065686-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1859807/000121390025065686/ea0249267-8k_profusa.htm
  HTML page:      https://secwatch.observer/filing/0001213900-25-065686

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer